Anton Simeonov

Dr. Anton Simeonov

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2010 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
WLWendy A Lea
Wendy A Lea
Anton SimeonovAnton Simeonov
Anton Simeonov
Importance of the field: Fluorescence polarization (FP) is a homogeneous method that allows rapid and quantitative analysis of diverse molecular interactions and enzyme activities. This technique h...

11 June 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
RFRafaela S. Ferreira
Rafaela S. Ferreira
Anton SimeonovAnton Simeonov
Anton Simeonov
AJAjit Jadhav
Ajit Jadhav
OEOliv Eidam
Oliv Eidam
BMBryan T. Mott
Bryan T. Mott
BSBrian K. Shoichet
Brian K. Shoichet
Virtual and high-throughput screens (HTS) should have complementary strengths and weaknesses, but studies that prospectively and comprehensively compare them are rare. We undertook a parallel docking and HTS screen of 197861 compounds against cruzain, a thiol protease target for Chagas disease, looking for reversible, competitive inhibitors. On workup, 99% of the hits were eliminated as false positives, yielding 146 well-behaved, competitive ligands. These fell into five chemotypes: two were prioritized by scoring among the top 0.1% of the docking-ranked library, two were prioritized by behavior in the HTS and by clustering, and one chemotype was prioritized by both approaches. Determination of an inhibitor/cruzain crystal structure and comparison of the high-scoring docking hits to experiment illuminated the origins of docking false-negatives and false-positives. Prioritizing molecules that are both predicted by docking and are HTS-active yields well-behaved molecules, relatively unobscured by the false-positives to which both techniques are individually prone.

12 November 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AJAjit Jadhav
Ajit Jadhav
RFRafaela S. Ferreira
Rafaela S. Ferreira
CKCarleen Klumpp
Carleen Klumpp
BMBryan T. Mott
Bryan T. Mott
CAChristopher P. Austin
Christopher P. Austin
Anton SimeonovAnton Simeonov
Anton Simeonov

23 November 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OKOliver N. F. King
Oliver N. F. King
XLXuan Shirley Li
Xuan Shirley Li
MSMasaaki Sakurai
Masaaki Sakurai
AKAkane Kawamura
Akane Kawamura
NRNathan R. Rose
Nathan R. Rose
Anton SimeonovAnton Simeonov
Anton Simeonov
Small molecule modulators of epigenetic processes are currently sought as basic probes for biochemical mechanisms, and as starting points for development of therapeutic agents. Nε-Methylation of lysine residues on histone tails is one of a number of post-translational modifications that together enable transcriptional regulation. Histone lysine demethylases antagonize the action of histone methyltransferases in a site- and methylation state-specific manner. Nε-Methyllysine demethylases that use 2-oxoglutarate as co-factor are associated with diverse human diseases, including cancer, inflammation and X-linked mental retardation; they are proposed as targets for the therapeutic modulation of transcription. There are few reports on the identification of templates that are amenable to development as potent inhibitors in vivo and large diverse collections have yet to be exploited for the discovery of demethylase inhibitors. High-throughput screening of a ∼236,000-member collection of diverse molecules arrayed as dilution series was used to identify inhibitors of the JMJD2 (KDM4) family of 2-oxoglutarate-dependent histone demethylases. Initial screening hits were prioritized by a combination of cheminformatics, counterscreening using a coupled assay enzyme, and orthogonal confirmatory detection of inhibition by mass spectrometric assays. Follow-up studies were carried out on one of the series identified, 8-hydroxyquinolines, which were shown by crystallographic analyses to inhibit by binding to the active site Fe(II) and to modulate demethylation at the H3K9 locus in a cell-based assay. These studies demonstrate that diverse compound screening can yield novel inhibitors of 2OG dependent histone demethylases and provide starting points for the development of potent and selective agents to interrogate epigenetic regulation.

3 May 2021 in Nature Methods
Verified
Journal Article
Closed access
PDF file
YCYu Chen
Yu Chen
CTCarlos A. Tristan
Carlos A. Tristan
LCLu Chen
Lu Chen
VJVukasin M. Jovanovic
Vukasin M. Jovanovic
CMClaire Malley
Claire Malley
ISIlyas Singeç
Ilyas Singeç

1 November 2011 in Chemistry & Biology
Verified
Journal Article
Closed access
JCJunjun Chen
Junjun Chen
TDThomas S. Dexheimer
Thomas S. Dexheimer
YAYongxing Ai
Yongxing Ai
QLQin Liang
Qin Liang
MVMark A. Villamil
Mark A. Villamil
Zhihao ZhuangZhihao Zhuang
Zhihao Zhuang